It looks like you have an older browser that is not supported by this site. Please click here to update.

Article Open to All

Pfizer COVID-19 Vaccine Receives FDA Full Approval

Posted Aug 23, 20211 min Read

Regulatory & Clinical

The U.S. Food and Drug Administration (FDA) today granted full approval to the Pfizer-BioNTech COVID-19 Vaccine.

According to the FDA’s announcement, the vaccine will “now be marketed as Comirnaty, for the prevention of COVID-19 disease in individuals 16 years of age and older. The vaccine also continues to be available under emergency use authorization (EUA), including for individuals 12 through 15 years of age and for the administration of a third dose in certain immunocompromised individuals.”

Today’s approval means that this vaccine meets the highest safety and efficacy standards and is a big step in the fight against COVID-19.

For more information on this as well as the recently announced booster shot plan​, please see COVID-19 Vaccine: Boosters vs. Additional Doses for Immunocompromised​. ​​​

Read more